EP4713315A1 — Process for the preparation of deucravacitinib, and crystalline forms thereof
Assigned to Alivus Life Sciences Ltd · Expires 2026-03-25 · 0y expired
What this patent protects
The present invention relates to a process for the preparation of deucravacitinib. The present invention also relates to a novel intermediate of deucravacitinib, process for its preparation, and use thereof in the process for the preparation of deucravacitinib. The present invent…
USPTO Abstract
The present invention relates to a process for the preparation of deucravacitinib. The present invention also relates to a novel intermediate of deucravacitinib, process for its preparation, and use thereof in the process for the preparation of deucravacitinib. The present invention further relates to novel crystalline forms of deucravacitinib, and processes for their preparation. Further, the present invention relates to a process for the preparation of crystalline form A of deucravacitinib.
Drugs covered by this patent
- Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.